Kamada Ltd (KMDA) Receives $7.00 Average PT from Analysts

Kamada Ltd (NASDAQ:KMDA) has been assigned an average rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $7.00.

KMDA has been the subject of a number of recent research reports. ValuEngine downgraded shares of Kamada from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. TheStreet upgraded shares of Kamada from a “c” rating to a “b” rating in a research report on Friday, February 9th. Zacks Investment Research upgraded shares of Kamada from a “sell” rating to a “hold” rating in a research report on Friday, February 9th. HC Wainwright restated a “buy” rating on shares of Kamada in a research report on Thursday, February 8th. Finally, Chardan Capital initiated coverage on shares of Kamada in a research report on Friday, February 2nd. They set a “buy” rating and a $7.00 price objective for the company.

How to Become a New Pot Stock Millionaire

Kamada stock traded down $0.05 during trading on Wednesday, reaching $4.55. The stock had a trading volume of 17,634 shares, compared to its average volume of 20,231. Kamada has a 52-week low of $3.75 and a 52-week high of $8.61. The company has a quick ratio of 2.58, a current ratio of 3.30 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $185.21, a P/E ratio of 25.28 and a beta of 1.18.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.10. Kamada had a net margin of 6.71% and a return on equity of 9.06%. The company had revenue of $35.71 million during the quarter, compared to the consensus estimate of $32.90 million. research analysts anticipate that Kamada will post 0.21 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of KMDA. Meitav Dash Investments Ltd. purchased a new stake in shares of Kamada during the 4th quarter worth approximately $3,512,000. ARK Investment Management LLC purchased a new stake in shares of Kamada during the 4th quarter worth approximately $251,000. Finally, Jane Street Group LLC purchased a new stake in shares of Kamada during the 3rd quarter worth approximately $112,000. Institutional investors and hedge funds own 9.14% of the company’s stock.

WARNING: “Kamada Ltd (KMDA) Receives $7.00 Average PT from Analysts” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/21/kamada-ltd-kmda-receives-7-00-average-pt-from-analysts.html.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply